AB175. SOH25_AB_096. Differential levels of serum ferritin in patients with breast cancer following neoadjuvant chemotherapy
General Posters I

AB175. SOH25_AB_096. Differential levels of serum ferritin in patients with breast cancer following neoadjuvant chemotherapy

Talia Goodyear, Yeong Huei Desmond Chuah, Shona Tormey, Anne Merrigan, Juliette Buckley, Chwanrow Baban

Department of Breast Surgery, University Hospital Limerick, Limerick, Ireland

Background: Serum ferritin levels have been shown to be elevated in patients with breast cancer. There is evidence suggesting that elevated serum ferritin level is associated with worse outcomes for breast cancer patients. Thus, serum ferritin level has gained traction in recent years to be used as a prognostic marker for patients with breast cancer. However, there is a lack of evidence in the literature suggesting the validity of using serum ferritin level as a prognostic marker for patients with breast cancer. This study aimed to evaluate serum ferritin level as a prognostic marker in patients with breast cancer who had undergone neoadjuvant chemotherapy.

Methods: A retrospective analysis was performed using a breast cancer database in a tertiary university hospital. Patients diagnosed with breast cancers who underwent neo-adjuvant chemotherapy from 2021 to 2023 were included. Clinicopathological data, including tumour biomarkers and tumour size, were analysed. Serum ferritin levels were measured in patients with breast cancer following completion of neoadjuvant chemotherapy and at 1-year follow up.

Results: This study demonstrated differential ferritin levels in patients with breast cancer following neoadjuvant chemotherapy. The results from this study supported the utility of serum ferritin level as a prognostic marker in patients with breast cancer.

Conclusions: Serum ferritin levels have clinical utility in patients with breast cancer following neoadjuvant chemotherapy.

Keywords: Breast cancer; ferritin; neoadjuvant chemotherapy; prognostic marker; tumor biomarkers

Acknowledgments

None.

Footnote

Funding: None.

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-25-ab175
Cite this abstract as: Goodyear T, Chuah YHD, Tormey S, Merrigan A, Buckley J, Baban C. AB175. SOH25_AB_096. Differential levels of serum ferritin in patients with breast cancer following neoadjuvant chemotherapy. Mesentery Peritoneum 2025;9:AB175.

Article Options

Download Citation

Share